Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early loco-regional spread and distant metastases at diagnosis, leading to dismal prognosis with a 5-year overall survival rate moderately over than 5%. This malignancy is largely resistant to chemotherapy and radiation, but the reasons of the refractoriness to the therapies is still unknown. Evidence is accumulating to indicate that the PDAC microenvironment and vascularity strongly contribute to the clinical features of this disease. In particular, PDAC is characterized by excessive dense extracellular matrix deposition associated to vasculature collapse and hypoxia with low drug delivery, explaining at least partly the low efficacy of antiangiogenic drugs in this cancer. Strategies aimed to modulate tumor stroma favoring vasculature perfusion and chemotherapeutics delivery are under investigation.

Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue / Longo, Vito; Brunetti, Oronzo; Gnoni, Antonio; Cascinu, Stefano; Gasparini, Giampietro; Lorusso, Vito; Ribatti, Domenico; Silvestris, Nicola. - In: ONCOTARGET. - ISSN 1949-2553. - (2016), pp. 1-9. [10.18632/oncotarget.10765]

Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue

GNONI, antonio;CASCINU, Stefano;
2016

Abstract

Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early loco-regional spread and distant metastases at diagnosis, leading to dismal prognosis with a 5-year overall survival rate moderately over than 5%. This malignancy is largely resistant to chemotherapy and radiation, but the reasons of the refractoriness to the therapies is still unknown. Evidence is accumulating to indicate that the PDAC microenvironment and vascularity strongly contribute to the clinical features of this disease. In particular, PDAC is characterized by excessive dense extracellular matrix deposition associated to vasculature collapse and hypoxia with low drug delivery, explaining at least partly the low efficacy of antiangiogenic drugs in this cancer. Strategies aimed to modulate tumor stroma favoring vasculature perfusion and chemotherapeutics delivery are under investigation.
2016
1
9
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue / Longo, Vito; Brunetti, Oronzo; Gnoni, Antonio; Cascinu, Stefano; Gasparini, Giampietro; Lorusso, Vito; Ribatti, Domenico; Silvestris, Nicola. - In: ONCOTARGET. - ISSN 1949-2553. - (2016), pp. 1-9. [10.18632/oncotarget.10765]
Longo, Vito; Brunetti, Oronzo; Gnoni, Antonio; Cascinu, Stefano; Gasparini, Giampietro; Lorusso, Vito; Ribatti, Domenico; Silvestris, Nicola
File in questo prodotto:
File Dimensione Formato  
10765-163568-5-PB.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1108353
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 71
  • ???jsp.display-item.citation.isi??? 62
social impact